Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04347122 · ClinicalTrials.gov registry record · Phase 4
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction
A Phase 4 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT04347122 is a Phase 4 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT04347122, a Phase 4 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.
Interventions
- DRUG Tranexamic Acid (TXA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04347122
The ClinicalTrials.gov registry entry for NCT04347122 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tranexamic Acid (TXA) is the first listed.
NCT04347122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04347122 about?
NCT04347122 is a clinical study titled "Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction". This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.
What is the current status of trial NCT04347122?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2020-01-28. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT04347122?
The interventions under investigation include: Tranexamic Acid (TXA) (DRUG).
Who is sponsoring clinical trial NCT04347122?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.